Our top pick for
Vapotherm, Inc is a medical devices business based in the US. Vapotherm shares (VAPO) are listed on the NYSE and all prices are listed in US Dollars. Vapotherm employs 279 staff and has a trailing 12-month revenue of around USD$97.8 million.
Since the stock market crash in March caused by coronavirus, Vapotherm's share price has had significant positive movement.
Its last market close was USD$27.32, which is 65.85% up on its pre-crash value of USD$9.33 and 298.25% up on the lowest point reached during the March crash when the shares fell as low as USD$6.86.
If you had bought USD$1,000 worth of Vapotherm shares at the start of February 2020, those shares would have been worth USD$1,421.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,790.74.
|Latest market close||USD$27.32|
|52-week range||USD$6.86 - USD$54.42|
|50-day moving average||USD$28.6686|
|200-day moving average||USD$32.6989|
|Wall St. target price||USD$42.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.384|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||N/A|
|1 month (2020-10-27)||-9.57%|
|3 months (2020-08-23)||N/A|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-23)||N/A|
|2 years (2018-11-23)||N/A|
|3 years (2017-11-23)||N/A|
|5 years (2015-11-23)||N/A|
|Revenue TTM||USD$97.8 million|
|Gross profit TTM||USD$21.3 million|
|Return on assets TTM||-16.84%|
|Return on equity TTM||-48.29%|
|Market capitalisation||USD$668.7 million|
TTM: trailing 12 months
There are currently 2.4 million Vapotherm shares held short by investors – that's known as Vapotherm's "short interest". This figure is 4.1% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Vapotherm shares can be evaluated.
Vapotherm's "short interest ratio" (SIR) is the quantity of Vapotherm shares currently shorted divided by the average quantity of Vapotherm shares traded daily (recently around 501362.1399177). Vapotherm's SIR currently stands at 4.86. In other words for every 100,000 Vapotherm shares traded daily on the market, roughly 4860 shares are currently held short.
However Vapotherm's short interest can also be evaluated against the total number of Vapotherm shares, or, against the total number of tradable Vapotherm shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vapotherm's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Vapotherm shares in existence, roughly 100 shares are currently held short) or 0.1234% of the tradable shares (for every 100,000 tradable Vapotherm shares, roughly 123 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vapotherm.
Find out more about how you can short Vapotherm stock.
We're not expecting Vapotherm to pay a dividend over the next 12 months.
Vapotherm's shares were split on a 1:50 basis on 10 September 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vapotherm shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Vapotherm shares which in turn could have impacted Vapotherm's share price.
Over the last 12 months, Vapotherm's shares have ranged in value from as little as $6.86 up to $54.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Vapotherm's is -1.4272. This would suggest that Vapotherm's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vapotherm has bucked the trend.
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; tracheostomy adaptors; and ProSoft cannula to provide gentle contact with the skin. In addition, Vapotherm, Inc. offers aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.